GNRH1 and ovarian dysfunction: In these situations, the use of GnRH agonists might be considered.[24] Several clinical trials and meta-analyses have shown that premenopausal women who received ovarian function suppression using GnRH agonists while on chemotherapy were less likely to have ovarian failure and had higher rates of menses resumption compared to patients who did not.